Clinical Trials Directory

Trials / Completed

CompletedNCT03659799

Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes

A Double-blind, Randomized, Cross-over Study to Compare the Impact of Rapid-acting Insulin Aspart and Faster Acting Aspart (FiAsp) on Glucose Excursion During Postprandial Exercise in Adults With Type 1 Diabetes

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Institut de Recherches Cliniques de Montreal · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hypoglycemia is the main barrier for physical activity practice of patients with type 1 diabetes (T1D). For postprandial exercise, anticipation with meal insulin bolus reduction is the recommended method to reduce exercise-associated hypoglycemic risk. The impact of faster acting Aspart (FiAsp) pharmacokinetic on hypoglycemic risk has not yet been explored. This study will explore two different timings for exercise onset. Objective: To compare the impact of rapid-acting insulin Aspart and faster acting Aspart (FiAsp) on glucose reduction during exercise. Design: This study is a randomized, four-way, crossover study to compare the efficacy of 1) rapid-acting insulin Aspart, and 2) FiAsp on glucose reduction during an exercise performed 60 minutes or 120 minutes after breakfast. The insulin used and the timing of the exercise will be randomized. This project will be conducted at Institut de recherches cliniques de Montréal (IRCM, Montreal, Canada). Hypothesis: Faster acting Aspart (FiAsp) will be non-inferior to insulin Aspart for hypoglycemic risk.

Conditions

Interventions

TypeNameDescription
DRUGInsulin FiAspAn insulin bolus of FiAsp will be given 5 minutes before breakfast
DRUGInsulin AspartAn insulin bolus of Aspart will be given 5 minutes before breakfast
OTHER60-minutes postprandial exerciseA 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
OTHER120-minutes postprandial exerciseA 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast

Timeline

Start date
2019-04-12
Primary completion
2022-12-31
Completion
2023-03-30
First posted
2018-09-06
Last updated
2023-09-01

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03659799. Inclusion in this directory is not an endorsement.